RVMD - Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the company will deliver multiple presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 being held April 5-10, 2024, in San Diego, California.
Details of the planned presentations are listed below:
Revolution Medicines Oral Presentations:
| Title: |
| Discovery of RMC-9805, an Oral, RAS(ON) G12D-Selective Covalent Tri-Complex Inhibitor |
| Presenter: |
| John Knox, Ph.D. |
| Abstract Number: |
| ND03 |
| Session: |
| New Drugs on the Horizon: Part 1 |
| Date/Time: |
| 1:45 – 2:00 p.m. PT on April 7, 2024 |
| Title: |
| RMC-6236, a RAS(ON) Multi-Selective Tri-Complex Inhibitor |
| Presenter: |
| Elena Koltun, Ph.D., Wei Lin, M.D. |
| Session: |
| KRAS: Broadening the Attack Beyond G12C with Small Molecules and Immuno-Oncology |
| Date/Time: |
| 1:00 – 1:20 p.m. PT on April 9, 2024 |
| Title: |
| Combination of RAS(ON) G12C-Selective and Multi-Selective Tri-Complex Inhibitors Overcomes Resistance and Prolongs Durability in Preclinical Models of KRAS G12C NSCLC |
| Presenter: |
| Xing Wei, Ph.D. |
| Abstract Number: |
| 6585 |
| Session: |
| Novel Antitumor Agents 5 |
| Date/Time: |
| 2:35 – 2:50 p.m. PT on April 9, 2024 |
Revolution Medicines Poster Presentations:
| Title: |
| Potential Biomarkers of Response to the Combination of the RAS(ON) Multi-Selective Inhibitor RMC-6236 Plus Anti-PD-1 Antibody in Preclinical PDAC Models |
| Presenter: |
| Lillian Seu, Ph.D. |
| Abstract Number: |
| 581/4 |
| Session: |
| Immunotherapy |
| Date/Time: |
| 1:30 – 5:00 p.m. PT on April 7, 2024 |
| Title: |
| RMC-5127, a First-in-Class, Orally Bioavailable RAS(ON) G12V-Selective Tri-Complex Inhibitor, is CNS-Penetrant and Drives Regressions in Intracranially Implanted KRAS G12V Xenograft Tumors |
| Presenter: |
| Zhe Chen, M.B.B.S., Ph.D. |
| Abstract Number: |
| 3340/28 |
| Session: |
| Novel Antitumor Agents 3 |
| Date/Time: |
| 1:30 – 5:00 p.m. PT on April 8, 2024 |
| Title: |
| The RAS(ON) Multi-Selective Inhibitor RMC-7977 Blocks Downstream MAPK and PI3K Pathway Activation in KRAS G12X -Mutant Cancers |
| Presenter: |
| Priyanka Bapat, Ph.D. |
| Abstract Number: |
| 4709/2 |
| Session: |
| Other Cellular Mechanisms for Anticancer Drug Action |
| Date/Time: |
| 9:00 a.m. – 12:30 p.m. PT on April 9, 2024 |
Collaborator Poster Presentations:
| Title: |
| RTK Signaling and WT RAS Activity as Vulnerabilities in Tumors with Acquired Resistance to GDP-State Selective KRAS G12C Inhibitors in Preclinical Models |
| Lead RevMed Co-Author: |
| Harshit Shah, Ph.D. |
| Abstract Number: |
| 1924/2 |
| Session: |
| Drug Resistance 2: RAS GTPase |
| Date/Time: |
| 9:00 a.m. – 12:30 p.m. PT on April 8, 2024 |
| Title: |
| Resistance to RAS-GTP Inhibition in Models of Pancreatic Ductal Adenocarcinoma Arises Downstream of RAS Effectors |
| Lead RevMed Co-Author: |
| Jingjing Jiang, Ph.D. |
| Abstract Number: |
| 1927/5 |
| Session: |
| Drug Resistance 2: RAS GTPase |
| Date/Time: |
| 9:00 a.m. – 12:30 p.m. PT on April 8, 2024 |
Additional information on the AACR Annual Meeting 2024 is available through the AACR website at: https://www.aacr.org/meeting/aacr-annual-meeting-2024/
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional RAS(ON) mutant-selective inhibitors in the company’s development pipeline include RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C).
Media & Investor ContactErin Graves650-779-0136egraves@revmed.com